Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis
N.E. Verstegen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Suresh Senan(Amsterdam Neuroscience), Egbert F. Smit(Dutch Cancer Society), George Rodrigues(London Health Sciences Centre), Frank J. Lagerwaard(Amsterdam Neuroscience), R. Mollema(Medisch Centrum Alkmaar), A. van der Elst(Spaarne Ziekenhuis), Ben J. Slotman(Vrije Universiteit Amsterdam), Hanneke Joosten(Westfriesgasthuis), Willem F. van Tets(Sint Lucas Andreas Hospital), David A. Palma(Western University), M.I. Amir(Waterlandziekenhuis), Cornelis J.A. Haasbeek(University of Amsterdam), A. Warner(Cancer Care Ontario), J. Wolter Oosterhuis(Erasmus MC Cancer Institute)
Cited by 274
Related Papers
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k